Quviviq, a medication for insomnia, is available by prescription in the United States [1].
How is Quviviq prescribed?
Quviviq is prescribed by healthcare professionals for individuals struggling with insomnia [2]. It is available in tablet form with two dosage strengths, 25 mg and 50 mg [3].
What is the availability timeline for Quviviq?
Quviviq was approved by the U.S. Food and Drug Administration (FDA) in January 2023 [1]. Its availability to patients began shortly after this approval [1].
Who manufactures Quviviq?
Quviviq is manufactured by Idorsia Pharmaceuticals [4].
Where can I find more information on Quviviq patents?
DrugPatentWatch.com provides detailed information on pharmaceutical patents, including those related to Quviviq. You can visit DrugPatentWatch.com for the latest patent status and expiry dates [5].
What are the potential side effects of Quviviq?
Common side effects of Quviviq include dizziness, somnolence, and headache. Patients are advised to avoid driving or engaging in other potentially dangerous activities until they know how Quviviq affects them [2].
How does Quviviq work?
Quviviq is a dual-orexin receptor antagonist. It works by blocking the wake-promoting action of orexin neuropeptides in the brain, which helps to reduce sleep-promoting signals [2][3].
What is the difference between Quviviq and other insomnia treatments?
Unlike some other insomnia medications that can cause dependence or withdrawal symptoms, Quviviq is not a benzodiazepine and does not typically lead to these issues [2]. It targets the orexin system, which is a distinct pathway involved in regulating the sleep-wake cycle [3].
What clinical data supports Quviviq's use?
Clinical trials for Quviviq demonstrated its efficacy in improving sleep onset and sleep maintenance in adults with insomnia disorder [2].
Are there any restrictions on Quviviq use?
Quviviq is not recommended for individuals with narcolepsy due to the risk of hallucinations and sleep paralysis [2].
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-quviviq-quv-i-vik-tasimelteon-treatment-insomnia
[2] https://www.quviviq.com/
[3] https://www.idorsia.com/media/news-releases/idorsia-announces-fda-approval-of-quviviq-daridorexant-for-the-treatment-of-insomnia
[4] https://www.idorsia.com/
[5] https://drugpatentwatch.com/